WELL Health Technologies: Divestitures and Canadian Focus Could Lead to Valuation Re-Rating

WELL Health Technologies is a small-cap company that combines free cash flow, growth, and value. The company's focus on the Canadian market and recent divestitures could trigger a re-rating of its valuation. With a rare combination of attributes, WELL Health Technologies stands out in the market.

WELL Health Technologies (WELL:CA) (OTC:WHTCF) has been a subject of interest for investors due to its unique combination of free cash flow, growth, and value. The company's recent focus on the Canadian market and planned divestitures could trigger a re-rating of its valuation, making it an attractive opportunity for investors.

Strong Q1 Results

WELL Health's Q1-2025 results were solid, with revenue growing by 32% year-over-year (YoY) to $294.1 million. The company's adjusted EBITDA also grew by 36% to $27.6 million, with adjusted EBITDA attributable to WELL shareholders increasing by 29.2% to $20.293 million [1]. The company achieved 1.6 million patient visits in Q1, a 23% increase YoY, driven by a 29% increase in Canadian patient services visits [1].

Divestitures and Focus on Canada

WELL Health plans to divest four US assets: Circle Medical, WISP, CRH Medical, and CRH's provider staffing business. The company expects to fully exit its US care delivery business within 1-2 years. This move is aimed at unlocking value and raising cash to focus on more profitable Canadian operations [1]. The company's CEO, Hamed Shahbazi, stated that the decision to consolidate the care delivery business in Canada is based on higher returns on capital and less risk [1].

Buyback Program

During the Q1 earnings call, the company's CFO, Eva Fong, announced the reinitiation of the share buyback program. The company believes its shares are undervalued and aims to return value to shareholders [1]. The buyback program will involve purchasing up to 6.326 million shares, representing 2.5% of the outstanding share count [1].

Valuation and Growth Potential

WELL Health's enterprise value is approximately $1.36 billion, with a forward EV/EBITDA ratio of 12.3x, not factoring in future acquisitions. The company's growth potential is significant, with guidance suggesting annual revenue of $1.40 billion to $1.45 billion and adjusted EBITDA of $190 million to $210 million for 2025 [1]. Even after accounting for minority interest in subsidiaries like Healwell AI and WELLSTAR, the growth rate would still be solid.

Conclusion

WELL Health Technologies stands out in the market with its unique combination of attributes. The company's strong Q1 results, planned divestitures, and focus on the Canadian market present a compelling investment case. With a low forward EV/EBITDA ratio and significant growth potential, WELL Health could be undervalued, presenting an opportunity for investors.

References:

[1] https://seekingalpha.com/article/4789641-well-health-divestitures-canadian-focus-could-trigger-valuation-re-rating